研究单位：[1]Shanghai Pharmaceuticals Holding Co., Ltd[2]Anhui provincial hospital,Hefei,Anhui,China,230002[3]The First Affiliated Hospital of Anhui Medical University,Hefei,Anhui,China,230022[4]Affiliated Cancer Hospital, Sun Yat-sen University,Guangzhou,Guangdong,China,510060[5]Liuzhou people's Hospital,Liuzhou,Guangxi,China,545026[6]The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China,050011[7]Harbin Medical University cancer Hospital,Harbin,Heilongjiang,China,150081[8]Anyang Cancer Hospital,Anyang,Henan,China,455001[9]The First Affiliated Hospital of Henan University of Science and Technology,Luoyang,Henan,China,450052[10]Xiangyang Central Hospital,Xiangyang,Hubei,China,441021[11]Jiangsu Province Hospital,Nanjing,Jiangsu,China,210029[12]Jilin Cancer Hospital,Changchun,Jilin,China,130012[13]The first hospital of Jilin University,Changchun,Jilin,China,130061[14]General Hospital of Ningxia Medical University,Yinchuan,Ningxia,China,750003[15]The second people's hospital of neijiang,Neijiang,Sichuan,China,641199[16]Cancer Hospital of Xinjiang Medical University,Urumqi,Xinjiang,China,830054[17]Zhejiang cancer Hospital,Hangzhou,Zhejiang,China,310005[18]Peking Union Medical College Hospital,Beijing,China,100730[19]Chongqing University Three Gorges Hospital,Chongqing,China,404031
研究目的：
This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.
